David Kang Halozyme Therapeutics

David Kang heads the Drug Delivery Research team at Halozyme Therapeutics, and is a subject matter expert in recombinant human hyaluronidase facilitated rapid, high-volume subcutaneous administration of biotherapeutics. Prior to that, David spent over a decade between Pfizer and Schering-Plough researching oncology therapeutics and viral based gene delivery. He started his research career at the University of California at San Diego working on gene therapy approaches on infectious disease, where we also did his undergraduate studies in microbiology and graduate studies in virology.